5 Agents with other mechanisms of action were also shown to have significant neuroprotection in this model. The non-competitive NMDA antagonist, MK 801, showed significant neuroprotection in the model when given at 0.5 mg kg-', i.p. 30 min pre-ischaemia with t.i.d. dosing for 7 days (P< 0.001). The dihydropyridine calcium antagonist, nimodipine was not protective when given using the same dosing protocol as MK 801, 0.5 mg kg-' 30 min pre-occlusion and three times daily for 7 days but showed significant protection when given at 0.05 mg kg-' 15 min post-ischaemia and three times daily for 7 days. The lipid peroxidation inhibitor, tirilazad (single dose 1 mg kg-', i.v.) showed significant neuroprotection when given 5 min post-ischaemia but not when the first dose was delayed for 4 h.